<DOC>
	<DOCNO>NCT01135537</DOCNO>
	<brief_summary>This study describe pharmacokinetic disposition biologically active rabbit anti-thymocyte globulin ( rATG ) consistent dose 7.5 mg/kg/course give part condition regimen child undergo hematopoeitic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Pharmacokinetics Thymoglobulin Paediatric Haematopoietic Stem-cell Transplants</brief_title>
	<detailed_description>Allogeneic hematopoeitic stem cell transplantation ( HSCT ) therapeutic option patient malignancy well metabolic genetic disease . Conditioning regimen give prior donor cell infusion aim ablate recipient bone-marrow , allow engraftment stem-cells infuse , prevent acute versus host disease ( aGVHD ) . Anti-thymocyte globulin ( ATG ) one immunosuppressive drug give preparative regimen HSCT . Subjects give ATG infusion daily 3 day prior HSCT serum level collect , per schedule , last sample take +100 day post-HSCT .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>All patient schedule receive ATG 2.5mg/kg/day 3 day part preparative regimen HSCT , determine responsible HSCT physician . Written , inform consent Hypersensitivity rabbit protein product excipients Active acute chronic infection , would contraindicate additional immunosuppression Known pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pediatrics</keyword>
</DOC>